NO329931B1 - Kondenserte heterocykliske suksinimidforbindelser og analoger derav, farmasoytiske blandinger omfattende slike, slike forbindelser for bruk som medikament samt slike forbindelser for behandling av sykdom - Google Patents

Kondenserte heterocykliske suksinimidforbindelser og analoger derav, farmasoytiske blandinger omfattende slike, slike forbindelser for bruk som medikament samt slike forbindelser for behandling av sykdom Download PDF

Info

Publication number
NO329931B1
NO329931B1 NO20031266A NO20031266A NO329931B1 NO 329931 B1 NO329931 B1 NO 329931B1 NO 20031266 A NO20031266 A NO 20031266A NO 20031266 A NO20031266 A NO 20031266A NO 329931 B1 NO329931 B1 NO 329931B1
Authority
NO
Norway
Prior art keywords
epoxy
isoindole
dione
methyl
hexahydro
Prior art date
Application number
NO20031266A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031266D0 (no
NO20031266L (no
Inventor
Mark Ernest Salvati
James A Balog
Dacia A Pickering
Soeren Giese
Aberra Fura
Wenying Li
Ramesh N Patel
Ronald L Hanson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20031266D0 publication Critical patent/NO20031266D0/no
Publication of NO20031266L publication Critical patent/NO20031266L/no
Publication of NO329931B1 publication Critical patent/NO329931B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20031266A 2000-09-19 2003-03-19 Kondenserte heterocykliske suksinimidforbindelser og analoger derav, farmasoytiske blandinger omfattende slike, slike forbindelser for bruk som medikament samt slike forbindelser for behandling av sykdom NO329931B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23351900P 2000-09-19 2000-09-19
US28443801P 2001-04-18 2001-04-18
US28473001P 2001-04-18 2001-04-18
PCT/US2001/019655 WO2002024702A1 (en) 2000-09-19 2001-06-20 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (3)

Publication Number Publication Date
NO20031266D0 NO20031266D0 (no) 2003-03-19
NO20031266L NO20031266L (no) 2003-05-13
NO329931B1 true NO329931B1 (no) 2011-01-24

Family

ID=27398441

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031266A NO329931B1 (no) 2000-09-19 2003-03-19 Kondenserte heterocykliske suksinimidforbindelser og analoger derav, farmasoytiske blandinger omfattende slike, slike forbindelser for bruk som medikament samt slike forbindelser for behandling av sykdom

Country Status (36)

Country Link
US (1) US20040176324A1 (cs)
EP (1) EP1319007B9 (cs)
JP (1) JP4966477B2 (cs)
KR (1) KR100765670B1 (cs)
CN (2) CN1995039A (cs)
AR (1) AR035340A1 (cs)
AT (1) ATE318822T1 (cs)
AU (2) AU6994301A (cs)
BG (1) BG107675A (cs)
BR (1) BR0113980A (cs)
CA (1) CA2423071A1 (cs)
CZ (1) CZ2003780A3 (cs)
DE (1) DE60117551T2 (cs)
DK (1) DK1319007T3 (cs)
EE (1) EE200300108A (cs)
ES (1) ES2260244T3 (cs)
GE (1) GEP20074144B (cs)
HK (1) HK1054230B (cs)
HR (1) HRP20030305B9 (cs)
HU (1) HUP0400455A3 (cs)
IL (1) IL155019A0 (cs)
IS (1) IS6750A (cs)
MX (1) MXPA03002412A (cs)
MY (1) MY138531A (cs)
NO (1) NO329931B1 (cs)
NZ (1) NZ524803A (cs)
PE (1) PE20020729A1 (cs)
PL (1) PL361707A1 (cs)
PT (1) PT1319007E (cs)
SK (1) SK4982003A3 (cs)
TW (1) TWI305208B (cs)
UA (1) UA78686C2 (cs)
UY (1) UY26808A1 (cs)
WO (1) WO2002024702A1 (cs)
YU (1) YU20003A (cs)
ZA (1) ZA200302963B (cs)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) * 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US7649001B2 (en) 2002-08-12 2010-01-19 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
WO2004110978A2 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US8592452B2 (en) * 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
JPWO2008007664A1 (ja) * 2006-07-11 2009-12-10 武田薬品工業株式会社 二環性複素環化合物およびその用途
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR102559394B1 (ko) * 2018-06-14 2023-07-27 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 물질 사용 재발에 사용되는 비근육 미오신 ii 억제제
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022061226A1 (en) * 2020-09-19 2022-03-24 Augusta University Research Institute, Inc. Compositions and methods for inhibiting trem-1
CN115340483A (zh) * 2022-08-31 2022-11-15 南京吉星生物技术开发有限公司 一种萘基吡咯啉二酮化合物及其制备方法与它的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
JPS5046697A (cs) * 1973-08-20 1975-04-25
US5539126A (en) * 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
DE69533180T2 (de) * 1994-12-22 2005-07-14 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-Modulator Verbindungen und Methoden
WO1997049709A1 (en) * 1996-06-27 1997-12-31 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
AU6945898A (en) * 1997-04-29 1998-11-24 Salk Institute For Biological Studies, The Methods for identifying ligands for nuclear hormone receptors
US7101681B1 (en) * 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
AU6985300A (en) * 1999-09-10 2001-04-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6960474B2 (en) * 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Also Published As

Publication number Publication date
AU6994301A (en) 2002-04-02
WO2002024702A1 (en) 2002-03-28
JP4966477B2 (ja) 2012-07-04
GEP20074144B (en) 2007-07-10
TWI305208B (en) 2009-01-11
US20040176324A1 (en) 2004-09-09
PE20020729A1 (es) 2002-08-11
SK4982003A3 (en) 2004-05-04
CZ2003780A3 (cs) 2004-01-14
ES2260244T3 (es) 2006-11-01
DK1319007T3 (da) 2006-06-19
DE60117551T2 (de) 2007-01-18
HK1054230A1 (en) 2003-11-21
YU20003A (sh) 2006-03-03
HRP20030305A2 (en) 2005-04-30
JP2004509895A (ja) 2004-04-02
HUP0400455A3 (en) 2007-10-29
AR035340A1 (es) 2004-05-12
PT1319007E (pt) 2006-05-31
NO20031266D0 (no) 2003-03-19
EE200300108A (et) 2005-02-15
MXPA03002412A (es) 2004-05-05
UA78686C2 (en) 2007-04-25
CN1307181C (zh) 2007-03-28
EP1319007B1 (en) 2006-03-01
HUP0400455A2 (hu) 2004-06-28
EP1319007A1 (en) 2003-06-18
CA2423071A1 (en) 2002-03-28
KR100765670B1 (ko) 2007-10-10
KR20030028847A (ko) 2003-04-10
BR0113980A (pt) 2003-06-24
BG107675A (bg) 2003-12-31
CN1608069A (zh) 2005-04-20
PL361707A1 (en) 2004-10-04
IS6750A (is) 2003-03-18
MY138531A (en) 2009-06-30
NO20031266L (no) 2003-05-13
CN1995039A (zh) 2007-07-11
ATE318822T1 (de) 2006-03-15
ZA200302963B (en) 2004-07-15
AU2001269943B2 (en) 2006-11-09
EP1319007B9 (en) 2007-10-10
NZ524803A (en) 2004-09-24
DE60117551D1 (de) 2006-04-27
IL155019A0 (en) 2003-10-31
UY26808A1 (es) 2002-01-31
HK1054230B (en) 2006-07-28
HRP20030305B1 (en) 2007-12-31
HRP20030305B9 (en) 2008-03-31

Similar Documents

Publication Publication Date Title
NO329931B1 (no) Kondenserte heterocykliske suksinimidforbindelser og analoger derav, farmasoytiske blandinger omfattende slike, slike forbindelser for bruk som medikament samt slike forbindelser for behandling av sykdom
US7141578B2 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002361785B2 (en) Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
US7342034B2 (en) Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001269943A1 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20060111424A1 (en) Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US7655689B2 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
RU2298554C2 (ru) Конденсированные гетероциклические сукцинимидные соединения
KR20030014407A (ko) 융합 고리형 핵 호르몬 수용체 기능 조절체
AU2002250163A1 (en) Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees